Summary and Conclusion
HF presents with an apparent lung phenotype characterized by thickened
walls of small vessels within the lung and an elevation of
classically-activated non-alveolar macrophages. Pharmacological CFTR
correction with Lum attenuates HF-associated vascular alterations and
lowers pro-inflammatory macrophage numbers, while promoting an
alternatively-activated phenotype. Collectively, these data suggest
pharmacological CFTR correction as promising approach to mitigate
HF-induced pulmonary inflammation and associated structural alterations.